Obstet Gynecol Res 2021; 4 (1): 034-042 DOI: 10.26502/ogr053 Obstetrics and Gynecology Research - Vol. 4 No. 1 – March 2021. 34 Research Article Efficacy of Intravaginal Estrogen (Estriol) in Medical Management of Genitourinary Syndrome of Menopause in an Indian Asian Female Tanudeep Kaur 1* , Kumari Anukriti 2 , Jai Bhagwan Sharma 3 , Kavita Pandey 4 , Rajesh Kumari 5 1 Department of Urogynecology, AIIMS, New Delhi, India 2 Senior Resident, AIIMS, New Delhi, India 3 Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India 4 Gynaecologist and Obstetrician Doctor, New Delhi, India 5 Department of Obstetrics and Gynecology, Safdarjung Hospital and VMMC, New Delhi, India * Corresponding Author: Tanudeep Kaur, Department of Urogynecology, AIIMS, New Delhi, India, E-mail: tanibedi@gmail.com Received: 27 January 2021; Accepted: 05 February 2021; Published: 06 February 2021 Citation: Tanudeep Kaur, Kumari Anukriti, Jai Bhagwan Sharma, Kavita Pandey, Rajesh Kumari. Efficacy of Intravaginal Estrogen (Estriol) in Medical Management of Genitourinary Syndrome of Menopause in an Indian Asian Female. Obstetrics and Gynecology Research 4 (2021): 034-042. Abstract Background: As high as 60% of postmenopausal women suffer from atrophic urogenital symptoms called as Genitourinary Syndrome of Menopause (GSM), due to declining ovarian function. It causes moderate to severe bothersomeness. Effectiveness of locally applied estrogen over 12 weeks improves their general and sexual quality of life (QOL). Aims: We aimed to measure the most bothersome of the various symptoms (MBS), and Female sexual dysfunction (FSD) on a validated Female Sexual Function Index (FSFI) scale and their self reported severity improvement over 12 weeks. Material and methods: A prospective cohort study of 100 menopausal women with at least one of the various GSM symptoms to assess for the MBS, severity of various GSM symptoms and FSFI scoring; as well as to assess their improvement after 12 weeks of local vaginal